| Autor: |
Silva-Fernández L; Servicio de Reumatología, Hospital Universitario Puerta de Hierro, Madrid, Spain. lsilvaf.hpth@salud.madrid.org, Andreu-Sánchez JL, Ginzler EM |
| Jazyk: |
angličtina |
| Zdroj: |
Revista clinica espanola [Rev Clin Esp] 2008 Mar; Vol. 208 (3), pp. 138-41. |
| DOI: |
10.1157/13115822 |
| Abstrakt: |
Renal involvement in systemic lupus erythematosus (SLE) is an important cause of morbidity and mortality, reaching a prevalence of 39% during the course of the disease. Currently, the therapy for severe lupus nephritis is based on the use of high-dose corticosteroids and immunosuppressive drugs, being traditionally cyclophosphamide the most frequently used agent. Recent studies have demonstrated the efficacy of mycophenolate mofetil as induction therapy for lupus nephritis. Azathioprine, a safe drug during pregnancy, has not been demonstrated to be as effective as mycophenolate or cyclophosphamide as induction therapy, although it is an effective drug for maintenance of remission. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
